Journal article
Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status
Oncotarget, Vol.9(18), pp.14738-14740
03/06/2018
DOI: 10.18632/oncotarget.24553
PMCID: PMC5865703
PMID: 29581877
Abstract
Large cell neuroendocrine carcinomas (LCNEC) are a group of rare high grade neuroendocrine tumors that often behave clinically like small cell carcinoma (SCLC) and are treated as such. No major advancement in the management of these tumors has occurred in the last 30 years.
We present a case series of three cases from Markey Cancer center along with a review of 13 published cases in the literature wherein immune-checkpoint inhibitors were utilized in the management of LCNEC.
Immune-checkpoint inhibitors might have clinical activity in LCNEC.
Role of immune-checkpoint inhibitors should be explored in prospective LCNEC clinical trials. We summarize current evidence regarding use of immune checkpoint inhibitors in the treatment of LCNEC.
Details
- Title: Subtitle
- Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status
- Creators
- Aman Chauhan - Markey Cancer CenterSusanne M Arnold - University of KentuckyJill Kolesar - University of KentuckyHala Elnakat Thomas - University of CincinnatiMark Evers - University of KentuckyLowell Anthony - University of Kentucky
- Resource Type
- Journal article
- Publication Details
- Oncotarget, Vol.9(18), pp.14738-14740
- DOI
- 10.18632/oncotarget.24553
- PMID
- 29581877
- PMCID
- PMC5865703
- NLM abbreviation
- Oncotarget
- ISSN
- 1949-2553
- eISSN
- 1949-2553
- Publisher
- Impact Journals LLC
- Language
- English
- Date published
- 03/06/2018
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984696538402771
Metrics
2 Record Views